2738-LB: Real-World Outcomes of Topical Ionic Cofactor Delivery in Diabetic Foot Complications Refractory to Standard of Care: A Retrospective Analysis

Introduction and Objective: DFU and DFI remain leading causes of nontraumatic lower-extremity amputation. SOC frequently fails to achieve closure. Zinc and copper are required cofactors for antimicrobial defense, collagen synthesis, and angiogenesis; local depletion in metabolically compromised tissue may contribute to wound stasis. A topical ionic cofactor matrix (ICM), a Class II medical device approved outside the USA, delivers bioavailable metallic ions to the wound bed. This study evaluated ICM outcomes in persons with DFU and DFI refractory to SOC. Methods: Retrospective analysis of 36 consecutive diabetic foot cases (DFU n=22, DFI n=14) across severity grades, treated with ICM after documented SOC failure. No cases were excluded. Results: Mean wound volume reduction was 79.4% over 24.5 days. Results by subgroup are shown in Table 1. No adverse events, toxicity, or microbial resistance were observed. Conclusion: In persons with diabetic foot complications defined by SOC failure, topical ionic cofactor delivery produced clinically meaningful improvement across severity grades, with the strongest outcomes in the most severe presentations. Controlled investigation is warranted. Disclosure J. Petersen: None.